4503.T

Astellas Pharma Inc. [4503.T] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

4503.T Stock Summary

Earnings have grown 17.16% per last year.

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Earnings are expected to fall -100% next year

Profit margins (0.02%) are lower than the previous year (0.07%)

Top 10 Correlated Stocks

4503.T

In the News

4503.T Financial details

Company Rating

Strong Buy

Market Cap

2816.78B

Income

58M

Revenue

1543.32B

Book val./share

838.42

Cash/share

159.2

Dividend

Dividend %

3.69%

Employees

14.48K

Optionable

Shortable

Yes

Earnings

25 Apr 2024

P/E

93.54

Forward P/E

PEG

-9.39

P/S

2.07

P/B

1.94

P/C

9.3

P/FCF

22.44

Quick Ratio

0.75

Current Ratio

0.96

Debt / Equity

0.58

LT Debt / Equity

0.31

EPS (TTM)

0.25

EPS next Y

EPS next Q

EPS this Y

-19.14%

EPS next Y

EPS next 5Y

EPS last 5Y

-13.96%

Revenue last 5Y

3.06%

Revenue Q/Q

7.6%

EPS Q/Q

-1098.77%

SMA20

-7.06%

SMA50

-10.04%

SMA100

-14.98%

Inst Own

Inst Trans

ROA

ROE

ROC

0.03%

Gross Margin

82%

Oper. Margin

Profit Margin

Payout

320%

Shs Outstand

Shs Float

Target Price

52W Range

1551.0-2360.5

52W High

-37.27%

52W Low

-4.55%

RSI

Rel Volume

0.94

Avg Volume

8.41M

Volume

7.91M

Perf Week

-5.94%

Perf Month

-7.41%

Perf Quarter

-23.43%

Perf Half Y

-23.11%

Beta

0.28

Volatility

53.42%, 67.45%

Prev Close

1.02%

Price

1480.5

Change

0.95%

4503.T Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	676.2	693.34	672.83	700.74	834.4
Net income per share	115.05	104.15	64.93	67.08	54.24
Operating cash flow per share	133.87	118.32	165.22	139.18	180.09
Free cash flow per share	106.89	76.81	123.53	97.85	131.44
Cash per share	162.37	174.74	178.6	182.34	217.92
Book value per share	651.38	687.12	746.38	789.48	828.54
Tangible book value per share	312.04	150.92	242.67	288.61	339.03
Share holders equity per share	651.38	687.12	746.38	789.48	828.54
Interest debt per share	1.71	186.68	117.84	88.31	83.26
Market cap	3273.57B	3135.12B	3160.83B	3534.8B	3427.1B
Enterprise value	2963.7B	3230.06B	3112.96B	3431.56B	3250.26B
P/E ratio	14.73	16.04	26.21	28.49	34.72
Price to sales ratio	2.51	2.41	2.53	2.73	2.26
POCF ratio	12.66	14.12	10.3	13.73	10.46
PFCF ratio	15.85	21.76	13.78	19.53	14.33
P/B Ratio	2.6	2.43	2.28	2.42	2.27
PTB ratio	2.6	2.43	2.28	2.42	2.27
EV to sales	2.27	2.48	2.49	2.65	2.14
Enterprise value over EBITDA	9.45	10.26	14.13	15.79	13.18
EV to operating cash flow	11.46	14.55	10.15	13.33	9.92
EV to free cash flow	14.35	22.41	13.57	18.96	13.59
Earnings yield	0.07	0.06	0.04	0.04	0.03
Free cash flow yield	0.06	0.05	0.07	0.05	0.07
Debt to equity	0	0.27	0.16	0.11	0.09
Debt to assets	0	0.15	0.1	0.07	0.06
Net debt to EBITDA	-0.99	0.3	-0.22	-0.48	-0.72
Current ratio	1.72	1.09	1.47	1.34	1.45
Interest coverage	187.34	81.22	58.27	31.46	15.15
Income quality	1.04	0.9	2.11	1.64	2.48
Dividend Yield	0.02	0.02	0.02	0.02	0.03
Payout ratio	0.32	0.38	0.63	0.69	1.02
Sales general and administrative to revenue	0.38	0.38	0.4	0.42	0.42
Research and developement to revenue	0.16	0.17	0.18	0.19	0.18
Intangibles to total assets	0.35	0.43	0.41	0.4	0.36
Capex to operating cash flow	-0.2	-0.35	-0.25	-0.3	-0.27
Capex to revenue	-0.04	-0.06	-0.06	-0.06	-0.06
Capex to depreciation	-0.82	-1.17	-1.07	-0.96	-0.84
Stock based compensation to revenue	0	0	0	0	0
Graham number	1.3K	1.27K	1.04K	1.09K	1.01K
ROIC	0.17	0.11	0.07	0.07	0.06
Return on tangible assets	0.18	0.15	0.09	0.09	0.06
Graham Net	13.12	-185.31	-110.88	-83.94	-71.35
Working capital	359.49B	68.81B	280.22B	235.94B	323.92B
Tangible asset value	602.83B	283.15B	450.68B	533.85B	617.05B
Net current asset value	217.91B	-161.48B	-14.93B	51.27B	101.39B
Invested capital	0	0.27	0.16	0.11	0.09
Average receivables	352.59B	368.74B	363.88B	380.58B	425.26B
Average payables	163.09B	178.62B	148.37B	127.76B	135.49B
Average inventory	149.57B	151.26B	157.55B	158.58B	163.73B
Days sales outstanding	102.51	103.99	104.33	113.77	107.32
Days payables outstanding	231.56	226.8	185.09	188.61	177.51
Days of inventory on hand	189.36	199.18	243.39	220.83	220.74
Receivables turnover	3.56	3.51	3.5	3.21	3.4
Payables turnover	1.58	1.61	1.97	1.94	2.06
Inventory turnover	1.93	1.83	1.5	1.65	1.65
ROE	0.18	0.15	0.09	0.08	0.07
Capex per share	-26.98	-41.51	-41.7	-41.33	-48.65

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	220.65	195.77	209	218.73	235.33
Net income per share	26.56	-25.49	18.46	-0.81	8.09
Operating cash flow per share	39.68	63.88	6.8	20.57	28.68
Free cash flow per share	28.3	48.34	-2.32	3.32	20.16
Cash per share	226.75	219.19	335.98	202.83	159.2
Book value per share	861.58	833.34	879.73	914.38	838.42
Tangible book value per share	345.54	341	352.42	-165.67	-187.99
Share holders equity per share	861.58	833.34	879.73	914.38	838.42
Interest debt per share	3.94	77.71	201.6	497.46	487.36
Market cap	3657.31B	3407.35B	3855.77B	3718.38B	3022.93B
Enterprise value	3424.23B	3230.52B	3653.28B	4274B	3639.94B
P/E ratio	18.89	-18.47	29.1	-637.15	52.07
Price to sales ratio	9.09	9.62	10.28	9.48	7.16
POCF ratio	50.57	29.48	316.1	100.81	58.8
PFCF ratio	70.9	38.95	-925.75	625.57	83.64
P/B Ratio	2.33	2.26	2.44	2.27	2.01
PTB ratio	2.33	2.26	2.44	2.27	2.01
EV to sales	8.51	9.12	9.74	10.9	8.63
Enterprise value over EBITDA	40.04	-141.74	50.21	114.89	54.48
EV to operating cash flow	47.35	27.95	299.5	115.88	70.8
EV to free cash flow	66.38	36.93	-877.14	719.04	100.71
Earnings yield	0.01	-0.01	0.01	0	0
Free cash flow yield	0.01	0.03	0	0	0.01
Debt to equity	0	0.09	0.23	0.54	0.58
Debt to assets	0	0.06	0.13	0.25	0.26
Net debt to EBITDA	-2.73	7.76	-2.78	14.94	9.24
Current ratio	1.52	1.45	1.33	0.96	0.91
Interest coverage	21.9	-23.29	16.84	2.3	6.7
Income quality	1.21	-2.41	0.26	6.92	2.4
Dividend Yield	0.01	0	0.01	0	0.02
Payout ratio	1.13	0	1.63	0	4.32
Sales general and administrative to revenue	0.41	0.45	0.45	0.46	0.47
Research and developement to revenue	0.17	0.2	0.17	0.2	0.18
Intangibles to total assets	0.37	0.36	0.34	0.55	0.55
Capex to operating cash flow	-0.29	-0.24	-1.34	-0.84	-0.3
Capex to revenue	-0.05	-0.08	-0.04	-0.08	-0.04
Capex to depreciation	-0.9	-1.22	-0.7	-0.79	-0.33
Stock based compensation to revenue	0	0	0	0	0
Graham number	717.5	691.33	604.55	129.39	390.76
ROIC	0.03	-0.03	0.02	0	0.01
Return on tangible assets	0.03	-0.03	0.02	0	0.01
Graham Net	-55.11	-71.76	-87.95	-587.8	-606.08
Working capital	366.69B	323.92B	325.96B	-45.5B	-103.61B
Tangible asset value	629.82B	617.05B	632.31B	-297.03B	-337.06B
Net current asset value	129.07B	101.39B	97.91B	-786.92B	-815.33B
Invested capital	0	0.09	0.23	0.54	0.58
Average receivables	463.86B	455.36B	462.47B	492.11B	506.45B
Average payables	140.38B	137.24B	139.34B	142.84B	148.84B
Average inventory	165.93B	168.8B	187.31B	206.94B	219.81B
Days sales outstanding	103.88	113.44	114.82	116.09	108.16
Days payables outstanding	162.33	202.65	180.71	178.1	178.38
Days of inventory on hand	197.39	252	261.36	258.41	267.97
Receivables turnover	0.87	0.79	0.78	0.78	0.83
Payables turnover	0.55	0.44	0.5	0.51	0.5
Inventory turnover	0.46	0.36	0.34	0.35	0.34
ROE	0.03	-0.03	0.02	0	0.01
Capex per share	-11.37	-15.54	-9.12	-17.26	-8.52

4503.T Dividend History

4503.T Frequently Asked Questions

What is Astellas Pharma Inc. stock symbol ?

Astellas Pharma Inc. is a JP stock and trading under the symbol 4503.T

What is Astellas Pharma Inc. stock quote today ?

Astellas Pharma Inc. stock price is $1480.5 today.

Is Astellas Pharma Inc. stock public?

Yes, Astellas Pharma Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 8.41M
Market Capitalization 2816.78B
Employee 14.48K
CEO Mr. Naoki Okamura BSc
Headquarters Tokyo,JP
IPO Date 2000-01-04
Website https://www.astellas.com

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.